Bailitianheng (688506.SH): The self-developed global first-in-class EGFRHER3 dual antibody ADC drug Iza-bren has been included in the priority review program.

Smart Finance APP News, Baoli Tianheng (688506.SH) announced that recently, the company's independently developed EGFRHER3 dual-antibody ADC (iza-bren) which is the world's first and only new concept entering Phase III clinical trials, has been included in the National Medical Products Administration Drug Evaluation Center's priority review list. According to public information, iza-bren is also the world's first EGFRHER3 dual-antibody ADC to be included in the priority review list.